MAIA

MAIA Biotechnology, Inc.

1.03 USD

Last updated Nov 29, 08:23 UTC

Yesterday HIGH

$1.16

Yesterday LOW

$0.91

52w HIGH

$5.22

52w LOW

$0.91

EPS

-0.36

PE

-2.86

Next Earnings

Mar 22, 2024

Overview News Government Trades

MAIA Biotechnology, Inc. stock is down -48.5% since 30 days ago. The next earnings date is Mar 22, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 1 November’s closed higher than October.

We are a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. We were incorporated in Delaware in August 2018, and we have operations in Chicago, Illinois, with some of our team members setup virtually and working remotely in California, Nevada and Florida. Our principal executive office is located at 444 West Lake Street, Suite 1700, Chicago, IL.

Stock Exchange

NYSE

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

-

Website

MAIABiotech.com

Benzinga Newsdesk

Mon Jul 10, 2023

Maia Biotechnology Announced Updates On Preliminary Survival Data In The Part A Safety Lead-in Of Its Ongoing THIO-101 Phase 2 Trial Evaluating THIO In Sequential Combination With Cemiplimab In Advanced Non-small Cell Lung Cancer

First 2 patients dosed with THIO continue to be without documented progression for 12.2 and 11.5 months and remarkably without any new anti-cancer treatment 10.2 and 8.5 months after concluding treatment with THIO.
Benzinga Insights

Wed Jul 5, 2023

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights

Tue Jun 20, 2023

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Happy Mohamed

Tue Jun 20, 2023

MAIA Biotechnology Announces Updates In Enrollment In Phase II Clinical Trial: THIO-101 Has Enrolled 29 Patients

MAIA Biotechnology, Inc. (NYSE:MAIA) announced today that 29 patients have been dosed in MAIA's Phase 2 clinical trial, THIO-101, evaluating THIO in patients with advanced Non-Small Cell Lung Cancer (NSCLC). With the
Benzinga Newsdesk

Wed Jun 7, 2023

MAIA Biotechnology Files Second Patent For New Telomere-Targeting Molecules Program

The studies, conducted in vitro in multiple cancer cell lines and in vivo in several pre-clinical cancer models, demonstrated the intended mechanism of action and high-level anti-cancer activity for these new molecules.
Benzinga Newsdesk

Mon May 8, 2023

MAIA Biotechnology Reported Net Loss Of Approximately $(4.1)M Vs. Approximately $(3.9)M YoY; Raised Approximately $5.75M In Gross Proceeds From Public Offering Of 2.56M Shares At $2.25/Share
Lisa Levin

Mon May 1, 2023

TRACON Pharmaceuticals And 2 Other Stocks Under $3 Insiders Are Aggressively Buying

The Dow Jones closed higher by more than 250 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Lisa Levin

Tue Apr 25, 2023

Why GE HealthCare Technologies Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Gainers
Benzinga Insights

Tue Apr 25, 2023

Stocks That Hit 52-Week Lows On Tuesday

Tuesday's session saw 286 companies set new 52-week lows.
Lisa Levin

Tue Apr 25, 2023

Nasdaq Down 50 Points; US Home Price Index Rises In February

U.S. stocks traded mostly lower this morning, with the Nasdaq Composite dropping around 50 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.01% to 33,872.34 while the NASDAQ fell 0.45% to 11,983.04. The S&P 500, also fell, dropping, 0.36% to 4,122.01.